Добірка наукової літератури з теми "T315I mutation"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "T315I mutation".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "T315I mutation"
Chen, Jiaqi, Hongxing Liu, Fang Wang, Yang Zhang, Xue Chen, Daijing Nie, Yu Li, Yincheng Tan, Yuanli Xu, and Xiaoli Ma. "Dynamic Evolution of Ponatinib Resistant BCR-ABL1 T315 and Compound Mutations." Blood 134, Supplement_1 (November 13, 2019): 3796. http://dx.doi.org/10.1182/blood-2019-129579.
Повний текст джерелаManrique, Gonzalo, Roberta Bittencout, Verónica Pérez, Vanesa Sholl, Monica Cappetta, Noel Zubillaga, Rocio Hassan, et al. "Detection of BCR-ABL Kinase Domain Mutations in Chronic Myeloid Leukemia Patients Treated with Tirosin-Kinase Inhibitors." Blood 112, no. 11 (November 16, 2008): 4261. http://dx.doi.org/10.1182/blood.v112.11.4261.4261.
Повний текст джерелаSoverini, Simona, Giovanni Martinelli, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Gianantonio Rosti, Costanza Bosi, et al. "Mutations at Residues 315 and 317 in the ABL Kinase Domain Are the Main Cause of Resistance to Dasatinib in Philadelphia-Positive (Ph+) Leukemia Patients (pts)." Blood 108, no. 11 (November 16, 2006): 836. http://dx.doi.org/10.1182/blood.v108.11.836.836.
Повний текст джерелаSmith, Catherine C., Michael Brown, Jason Chin, Corynn Kasap, Sara Salerno, Lauren E. Damon, Kevin Travers, et al. "Single Molecule Real Time (SMRT™) Sequencing Sensitively Detects Polyclonal and Compound BCR-ABL in Patients Who Relapse on Kinase Inhibitor Therapy,." Blood 118, no. 21 (November 18, 2011): 3752. http://dx.doi.org/10.1182/blood.v118.21.3752.3752.
Повний текст джерелаShah, Neil P., John M. Nicoll, Susan Branford, Timothy P. Hughes, Ronald L. Paquette, Moshe Talpaz, Claude Nicaise, Fei Huang, and Charles L. Sawyers. "Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy." Blood 106, no. 11 (November 16, 2005): 1093. http://dx.doi.org/10.1182/blood.v106.11.1093.1093.
Повний текст джерелаDeininger, Michael W. N., Michael J. Mauro, Yousif Matloub, Ritwik Sinha, Lynn Ploughman, David Liu, and Jerald Radich. "Prevalence of T315I, Dasatinib-Specific Resistant Mutations (F317L, V299L, and T315A), and Nilotinib-Specific Resistant Mutations (P-loop and F359) at the Time of Imatinib Resistance in Chronic-Phase Chronic Myeloid Leukemia (CP-CML)." Blood 112, no. 11 (November 16, 2008): 3236. http://dx.doi.org/10.1182/blood.v112.11.3236.3236.
Повний текст джерелаKim, Dong-Wook, Dongho Kim, Soo-Hyun Kim, Saengsuree Jootar, Hyun-Gyung Goh, Jeong Lee, Soo-Young Choi, Young-Seok Lee, and Sang-Mi Oh. "Dynamics and Characteristics of BCR-ABL Multiple Mutations In Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia." Blood 116, no. 21 (November 19, 2010): 3443. http://dx.doi.org/10.1182/blood.v116.21.3443.3443.
Повний текст джерелаDeininger, Michael W. N., Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, et al. "Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 7001. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.7001.
Повний текст джерелаJabbour, Elias, Hagop Kantarjian, Dan Jones, Srdan Verstovsek, Alessandra Ferrajoli, Farhad Ravandi, Susan O’Brien, and Jorge Cortes. "Characteristics and Outcome of Patients with Chronic Myeloid Leukemia (CML) and T315I Mutation Following Failure of Imatinib Mesylate Therapy." Blood 110, no. 11 (November 16, 2007): 1943. http://dx.doi.org/10.1182/blood.v110.11.1943.1943.
Повний текст джерелаJabbour, Elias, Hagop Kantarjian, Dan Jones, Megan Breeden, Guillermo Garcia-Manero, Susan O'Brien, Farhad Ravandi, Gautam Borthakur, and Jorge Cortes. "Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy." Blood 112, no. 1 (July 1, 2008): 53–55. http://dx.doi.org/10.1182/blood-2007-11-123950.
Повний текст джерелаДисертації з теми "T315I mutation"
Nagao, Rina. "Growth inhibition of imatinib-resistant CML cells with the T315I mutation and hypoxia-adaptation by AV65 - a novel Wnt/β-catenin signaling inhibitor". Kyoto University, 2012. http://hdl.handle.net/2433/157488.
Повний текст джерелаLee, Oi-Lin. "The role of cytokines in governing the expansion of the T315I mutation in chronic myeloid leukaemia." Thesis, 2014. http://hdl.handle.net/2440/95313.
Повний текст джерелаThesis (M.Phil.) -- University of Adelaide, School of Medicine, 2014
Частини книг з теми "T315I mutation"
Noronha, Glen, Jianguo Cao, Chun Chow, Elena Dneprovskaia, Linda Hwang, Dan Lohse, Chi Ching Mak, et al. "Targeting Drug Resistant Mutations Using Novel Binding Interactions - Lessons Learned from Abl-T315I and their Implications in D." In Frontiers in Drug Design & Discovery (Volume 3), 121–44. BENTHAM SCIENCE PUBLISHERS, 2012. http://dx.doi.org/10.2174/978160805201110703010121.
Повний текст джерелаТези доповідей конференцій з теми "T315I mutation"
Hong, Soon-Sun, Soo Jung Kim, Kyung Hee Jung, Hong Hua Yan, Zhenghuan Fang, Joo Han Lim, and Jeong Seon Ryu. "Abstract 5389: Novel kinase inhibitor for imatinib-resistant chronic myeloid leukemia with T315I mutation." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-5389.
Повний текст джерелаGupta, Pranav, Guannan Zhang, Anna Maria Barbuti, Ke Ding, Jingxuan Pan, Brian J. Druker, and Zhe-Sheng Chen. "Abstract 1980: S116836 overcomes BCR-ABL T315I mutation mediated imatinib resistance in chronic myeloid leukemia." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-1980.
Повний текст джерелаZhu, Xiaotian, Tianjun Zhou, William C. Shakespeare, Wei-Sheng Huang, Lois Commodore, Chester A. Metcalf, Yihan Wang, et al. "Abstract 2671: Structural analysis of the inhibitory mechanism of AP24534, a pan-BCR-ABL inhibitor overriding the T315I gatekeeper mutation." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-2671.
Повний текст джерелаGupta, Pranav, Rishil Kathawala, Liuya Wei, Fang Wang, XiaoKun Wang, Brian J. Druker, Li-Wu FU, and Zhe-Sheng Chen. "Abstract 4158: Targeting the imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia through a novel BCR-ABL inhibitor." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4158.
Повний текст джерела